申请人:Bristol-Myers Squibb Company
公开号:US05869509A1
公开(公告)日:1999-02-09
Novel compounds of Formula 1 are useful to treat disorders responsive to openers of the large conductance calcium-activated potassium channels: ##STR1## wherein "Het" is one of a select group of heterocyclic moieties; Z is independently for each occurrence selected from O or S; R.sup.a, R.sup.b and R.sup.c each are independently selected from hydrogen, halogen, OH, CF.sub.3, ##STR2## provided R.sup.c is not hydrogen; and when R.sup.a and R.sup.b are hydrogen, R.sup.c may be a heterocyclic moiety selected from the group consisting of imidazol-1-yl, morpholinomethyl, N-methylimidazol- 2-yl, and pyridinyl; R.sup.d and R.sup.e each are independently selected from hydrogen, halogen, CF.sub.3, NO.sub.2 or imidazol-1-yl; m, n and p each are independently selected from an integer of O or 1; and R.sup.f and R.sup.g each are independently hydrogen; C.sub.1-4 alkyl; or R.sup.f and R.sup.g, taken together with the nitrogen atom to which they are attached, is a heterocyclic moiety selected from the group consisting of N-methylpiperazine, morpholine, thiomorpholine, N-benzylpiperazine and imidazolinone.
化合物1的新型化合物可用于治疗对大导电性钙激活钾通道开放剂反应的疾病:其中"Het"是一组特定的杂环基团之一;Z独立地为每次出现选择O或S;R.sup.a,R.sup.b和R.sup.c各自独立地选择氢,卤素,OH,CF.sub.3,provided R.sup.c不是氢;当R.sup.a和R.sup.b为氢时,R.sup.c可以是从咪唑-1-yl,morpholinomethyl,N-甲基咪唑-2-yl和吡啶基中选择的杂环基团之一;R.sup.d和R.sup.e各自独立地选择氢,卤素,CF.sub.3,NO.sub.2或咪唑-1-yl;m,n和p各自独立地选择O或1的整数;而R.sup.f和R.sup.g各自独立地选择氢;C.sub.1-4烷基;或R.sup.f和R.sup.g与它们所连接的氮原子一起选择从N-甲基哌嗪,morpholine,thiomorpholine,N-苄基哌嗪和咪唑啉酮中选择的杂环基团之一。